Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

Adaptive Biotechnologies (ADPT) reported $70.87 million in revenue for the quarter ended March 2026, representing a year-over-year increase of 35.2%. EPS of -$0.13 for the same period compares to -$0.20 a year ago.

The reported revenue represents a surprise of +14.61% over the Zacks Consensus Estimate of $61.84 million. With the consensus EPS estimate being -$0.16, the EPS surprise was +16.13%.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Adaptive Biotechnologies performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

ClonoSEQ test volume: 32,595 versus the three-analyst average estimate of 31,235. Revenue- Total Immune Medicine: $3.78 million versus the three-analyst average estimate of $6.23 million. The reported number represents a year-over-year change of -56.7%. Revenue- Total MRD: $67.09 million compared to the $55.23 million average estimate based on three analysts. The reported number represents a change of +53.5% year over year. Revenue- MRD revenue- Service: $58.09 million versus the three-analyst average estimate of $55.23 million. Revenue- Immune Medicine revenue- Service and licensing revenue: $3.78 million compared to the $6.54 million average estimate based on two analysts. The reported number represents a change of -26.2% year over year.

View all Key Company Metrics for Adaptive Biotechnologies here>>>

Shares of Adaptive Biotechnologies have returned +3% over the past month versus the Zacks S&P 500 composite's +9.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

Adaptive Biotechnologies Corporation (ADPT) : Free Stock Analysis Report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research

View Comments